CS Pharmaceuticals Announces Inclusion of BRONCHITOL® in Beijing City-Wide Health Insurance Programme and First Shipment

London, England, January 5, 2026 – CS Pharmaceuticals Ltd. (CSP), a British clinical stage speciality pharmaceutical company focused on first- and best-in-class ocular therapeutics and treatments for rare diseases in China, announced the inclusion of BRONCHITOL® in the Beijing City-Wide Health Insurance Programme and first shipment of BRONCHITOL® to China.

The inclusion of BRONCHITOL® in this insurance programme enables Chinese patients with the rare disease cystic fibrosis living in Beijing to be treated with a globally approved pharmaceutical product specifically indicated for cystic fibrosis and receive valuable reimbursement of the cost. Existing registered patients can receive 60% reimbursement, while new patients can enrol for a modest fee annually and receive 30% reimbursement. Cystic fibrosis is listed in the Chinese catalogue of rare diseases and BRONCHITOL® has been recommended in the China cystic fibrosis diagnosis and treatment guideline. BRONCHITOL® has been approved for use in the Beijing Tianzhu and Hainan Bo'ao pilot zones and the first shipment of BRONCHITOL® to China has now been successfully completed.

"We are delighted to announce the inclusion of BRONCHITOL® in the Beijing City-Wide Health Insurance Programme" said Darren Mercer, Chief Executive of CSP. "As part of our launch plan for BRONCHITOL®, we have now arranged the first shipment to China. In the coming months we look forward to working with Doctors at the Peking Union Medical College Hospital to initiate treatment of Chinese patients. Importantly patients living in Beijing will now be able to reclaim substantial and meaningful reimbursement of the costs of treatment with BRONCHITOL®."

About BRONCHITOL®
BRONCHITOL® is approved for the treatment of cystic fibrosis to help patients clear mucus from their lungs. It is a precision spray-dried form of mannitol, delivered to the lungs by a specially designed, portable inhaler. BRONCHITOL® works by rehydrating the airway/lung surface and promoting a productive cough.

BRONCHITOL® has been evaluated in three large-scale clinical trials and is approved in over 30 countries, including the United States, Europe, the United Kingdom, and Australia. Clinical trials have shown that BRONCHITOL® helps to increase mucus clearance, improve lung function and the quality of life of people living with cystic fibrosis.

In China, BRONCHITOL® is now approved in several pilot zones. BRONCHITOL® has been recommended in the China cystic fibrosis diagnosis and treatment guideline.

About Cystic Fibrosis
Cystic fibrosis, which is listed on the Chinese catalogue of rare diseases, is a greatly under-recognised condition in China with no approved pharmaceutical products. It is estimated there are 20,000 patients with cystic fibrosis in China, but many of these remain undiagnosed.

The underlying mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene that cause cystic fibrosis are different in the Chinese population compared to Caucasians. Specifically the *F508del* mutation, that is the target mechanism of action of drugs such as vanzacaftor, elexacaftor and tezacaftor, has not been reported in the Chinese population. CSP, working together with leaders in the treatment of Cystic Fibrosis in China, identified the underlying mechanism of action of BRONCHITOL® as conserved in Chinese and Caucasian patients and therefore ideal for introduction via the China pilot zones."

About CS Pharmaceuticals
CSP is a global specialty pharmaceutical company with a rich heritage and expertise in developing and commercialising products. CSP's focus is on the development and commercialisation of innovative ophthalmology, rare and speciality diseases to address high unmet medical needs and improve the lives of patients around the world.

CSP's global ophthalmology product, CSP-270, is for the treatment of Meibomian Gland Dysfunction. With excellent phase II clinical data, CSP-270 has the potential to be the first approved pharmaceutical product for MGD with forecasted sales potential of $1.3 to 2.5 billion US dollars.

CSP's first licensed rare disease product for patients with Cystic Fibrosis is now approved in several pilot zones in China. Cystic fibrosis remains a significantly under-recognised condition in China with no approved pharmaceutical products.

CSP is leveraging its unique cross-border business model and strong reputation to establish strategic partnerships with more pharmaceutical companies both in the West and in China as it continues to expand its portfolio.

www.cspharmaceuticals.com

Contacts
CS Pharmaceuticals
Darren Mercer, Chief Executive Officer Tel: +44 (0) 2038 573830